What is BBLG's current stock price?

BBLG (Bone Biologics Corporation) is currently trading at $1.27 with a market cap of $2.3M.

What sector is Bone Biologics Corporation in?

Bone Biologics Corporation (BBLG) operates in the Healthcare sector, specifically in the Medical - Devices industry.

InvestLog

BBLG Bone Biologics Corporation

Healthcare

$1.27+0.00%OpenMarket Cap: $2.3M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.47

P/S

0.00

EV/EBITDA

0.81

DCF Value

$4.22

FCF Yield

-117.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-50.4%

ROA

-57.4%

ROIC

-64.3%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-766.0K	$—
Q4 null	$0.00	$-684.6K	$—
FY null	$0.00	$-3.1M	$—
Q3 null	$0.00	$-666.7K	$—

Analyst Ratings

View All

Consensus

—

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

Walsh Deina Hofficer: Chief Financial Officer

SellWed Jan 21

Frelick Jeffofficer: Chief Executive Officer

SellWed Jan 21

Stroever Brucedirector

SellFri Jun 06

Meikle Phillip Terry IIdirector

SellFri Jun 06

Gagnon Robert E.director

SellFri Jun 06

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

Exchange

—

Beta

0.53

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.

Peers

INM